```

[Congressional Bills 107th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2172 Introduced in House (IH)]

107th CONGRESS
  1st Session
                                H. R. 2172

 To amend the Federal Food, Drug, and Cosmetic Act with respect to the 
               cloning of humans, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             June 14, 2001

     Mr. Greenwood (for himself, Mr. Wolf, Mr. Owens, Mr. Neal of 
Massachusetts, Mr. Pallone, Mrs. McCarthy of New York, Mr. Deutsch, Mr. 
  Gillmor, and Ms. DeGette) introduced the following bill; which was 
            referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
 To amend the Federal Food, Drug, and Cosmetic Act with respect to the 
               cloning of humans, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Cloning Prohibition Act of 2001''.

SEC. 2. PROHIBITION AGAINST HUMAN CLONING.

    (a) In General.--The Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 301 et seq.) is amended by adding at the end the following:

                       ``CHAPTER X--HUMAN CLONING

                  ``prohibition against human cloning

    ``Sec. 1001. (a) Nuclear Transfer Technology.--
            ``(1) In general.--It shall be unlawful for any person--
                    ``(A) to use or attempt to use human somatic cell 
                nuclear transfer technology with the intent to initiate 
                a pregnancy; or
                    ``(B) to ship or transport the cellular product 
                resulting from human somatic cell nuclear transfer 
                technology knowing that the product is intended to be 
                used to initiate a pregnancy.
            ``(2) Definition.--For purposes of this section, the term 
        `human somatic cell nuclear transfer technology' means 
        transferring the nucleus of a human somatic cell into an egg 
        cell from which the nucleus has been removed or rendered inert.
    ``(b) Rule of Construction.--This section may not be construed as 
applying to any of the following:
            ``(1) The use of somatic cell nuclear transfer technology 
        to clone molecules, DNA, cells, or tissues.
            ``(2) The use of mitochondrial, cytoplasmic, or gene 
        therapy.
            ``(3) The use of in vitro fertilization, the administration 
        of fertility-enhancing drugs, or the use of other medical 
        procedures to assist a woman in becoming or remaining pregnant.
            ``(4) The use of somatic cell nuclear transfer technology 
        to clone or otherwise create animals other than humans.
            ``(5) Any other activity (including biomedical, 
        microbiological, or agricultural research or practices) not 
        expressly prohibited in subsection (a).
    ``(c) Registration.--
            ``(1) In general.--Each individual who intends to perform 
        human somatic cell nuclear transfer technology shall, prior to 
        first performing such technology, register with the Secretary 
        his or her name and place of business (except that, in the case 
        of an individual who performed such technology before the date 
        of the enactment of the Cloning Prohibition Act of 2001, the 
        individual shall so register not later than 60 days after such 
        date). The Secretary may by regulation require that the 
        registration provide additional information regarding the 
        identity and business locations of the individual, and 
        information on the training and experience of the individual 
        regarding the performance of such technology.
            ``(2) Attestation.--A registration under paragraph (1) 
        shall include a statement, signed by the individual submitting 
        the registration, declaring that the individual is aware of the 
        prohibitions described in subsection (a) and will not engage in 
        any violation of such subsection.
            ``(3) Confidentiality.--Information provided in a 
        registration under paragraph (1) shall not be disclosed to the 
        public by the Secretary except to the extent that--
                    ``(A) the individual submitting the registration 
                has in writing authorized the disclosure; or
                    ``(B) the disclosure does not identify such 
                individual or any place of business of the individual.
    ``(d) Preemption of State Law.--This section supersedes any State 
or local law that--
            ``(1) establishes prohibitions, requirements, or 
        authorizations regarding human somatic cell nuclear transfer 
        technology that are different than, or in addition to, those 
        established in subsection (a) or (c); or
            ``(2) with respect to humans, prohibits or restricts 
        research regarding or practices constituting--
                    ``(A) somatic cell nuclear transfer;
                    ``(B) mitochondrial or cytoplasmic therapy; or
                    ``(C) the cloning of molecules, DNA, cells, 
                tissues, or organs;
except that this subsection does not apply to any State or local law 
that was in effect as of the day before the date of the enactment of 
the Cloning Prohibition Act of 2001.
    ``(e)  Sunset.--This section and section 301(bb) do not apply to 
any activity described in subsection (a) that occurs on or after the 
expiration of the 10-year period beginning on the date of the enactment 
of the Cloning Prohibition Act of 2001.
    ``(f) Right of Action.--This section may not be construed as 
establishing any private right of action.''.
    (b) Prohibited Acts.--
            (1) In general.--Section 301 of the Federal Food, Drug, and 
        Cosmetic Act (21 U.S.C. 331) is amended by adding at the end 
        the following:
    ``(bb) The violation of section 1001(a), or the failure to register 
in accordance with section 1001(c).''.
            (2) Criminal penalty.--Section 303(b) of the Federal Food, 
        Drug, and Cosmetic Act (21 U.S.C. 333(b)) is amended by adding 
        at the end the following:
    ``(7) Notwithstanding subsection (a), any person who violates 
section 301(bb) shall be imprisoned not more than 10 years or fined in 
accordance with title 18, United States Code, or both.''.
            (3) Civil penalty.--Section 303 of the Federal Food, Drug, 
        and Cosmetic Act (21 U.S.C. 333) is amended by adding at the 
        end the following:
    ``(h)(1) Any person who violates section 301(bb) shall be liable to 
the United States for a civil penalty in an amount not to exceed the 
greater of--
            ``(A) $1,000,000; or
            ``(B) an amount equal to the amount of any gross pecuniary 
        gain derived from such violation multiplied by 2.
    ``(2) Paragraphs (3) through (5) of subsection (g) apply with 
respect to a civil penalty under paragraph (1) of this subsection to 
the same extent and in the same manner as such paragraphs (3) through 
(5) apply with respect to a civil penalty under paragraph (1) or (2) of 
subsection (g).''.
            (4) Forfeiture.--Section 303 of the Federal Food, Drug, and 
        Cosmetic Act, as amended by paragraph (3), is amended by adding 
        at the end the following:
    ``(i) Any property, real or personal, derived from or used to 
commit a violation of section 301(bb), or any property traceable to 
such property, shall be subject to forfeiture to the United States.''.

SEC. 3. STUDY BY INSTITUTE OF MEDICINE.

    (a) In General.--The Secretary of Health and Human Services 
(referred to in this section as the ``Secretary'') shall request the 
Institute of Medicine to enter into an agreement with the Secretary 
under which such Institute conducts a study to--
            (1) review the current state of knowledge about the 
        biological properties of stem cells obtained from embryos, 
        fetal tissues, and adult tissues;
            (2) evaluate the current state of knowledge about 
        biological differences among stem cells obtained from embryos, 
        fetal tissues, and adult tissues and the consequences for 
        research and medicine; and
            (3) assess what is currently known about the ability of 
        stem cells to generate neurons, heart, kidney, blood, liver and 
        other tissues and the potential clinical uses of these tissues.
    (b) Other Entities.--If the Institute of Medicine declines to 
conduct the study described in subsection (a), the Secretary shall 
enter into an agreement with another appropriate public or nonprofit 
private entity to conduct the study.
    (c) Report.--The Secretary shall ensure that, not later than three 
years after the date of the enactment of this Act, the study required 
in subsection (a) is completed and a report describing the findings 
made in the study is submitted to the Committee on Energy and Commerce 
in the House of Representatives and the Committee on Health, Education, 
Labor, and Pensions in the Senate.
                                 <all>
```